Jun. 11 at 5:21 AM
$AVXL ACCESS-AD will have a strong presence at the Alzheimer Europe conference in October, with 3 presentations currently listed in the program. Notably, blarcamesine continues to be integrated directly into the core project overview abstract as an established, baseline asset:
“Prospective studies will evaluate DMTs (such as anti-amyloid therapies and blarcamesine) in real-world practice, both alone and in combination with lifestyle interventions and nutritional strategies. Data on DMT safety, useability and clinical outcomes will be collected through InRAD’s pan-European AD registry, with the EPND Hub enabling discovery, sharing and re-use of cohort data...”
It is highly encouraging to see confirmation of blarcamesine’s ongoing, fundamental role within this important program. It will be interesting to see if new information about the planned studies will be shared at, or leading up to, this conference.
Links to the ACCESS-AD conference listings are included in the comments.
